E-viri
PDF
Recenzirano
Odprti dostop
-
Muir, A J; Gong, L; Johnson, S G; Lee, M T M; Williams, M S; Klein, T E; Caudle, K E; Nelson, D R
Clinical pharmacology and therapeutics, February 2014, Letnik: 95, Številka: 2Journal Article
Pegylated interferon‐α (PEG‐IFN‐α or PEG‐IFN 2a and 2b)– and ribavirin (RBV)‐based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG‐IFN‐α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision‐making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG‐IFN‐α‐ and RBV‐containing regimens based on IFNL3 genotype. Clinical Pharmacology & Therapeutics (2014); 95 2, 141–146. doi:10.1038/clpt.2013.203
